Management of Heart Failure: Time to Consider New Options?

Management of Heart Failure: Time to Consider New Options?

Management of Heart Failure: Time to Consider New Options?

Find out how providers can manage potassium levels while ensuring that patients with heart failure receive the full benefit of RAASi therapies.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Derangements in potassium levels are associated with poor outcomes in patients with heart failure. At the same time, suboptimal use of renin-angiotensin-aldosterone system inhibitor (RAASi) therapies is associated with an increased risk of death. So how do we as clinicians balance these risks?

    This discussion focuses on how providers can maximize the use RAASi therapies in patients with heart failure while simultaneously employing potassium binders to manage hyperkalemia. 

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Austin G. Stack, MBBCh, MD, MSc, FASN, FRCPI
    Professor and Chair of Medicine
    University of Limerick (UL) School of Medicine & University Hospital Limerick
    Limerick, Ireland 

    Commercial Interest Speakers Bureau: AstraZeneca, Vifor Pharma
    Consulting Fees: Astellas, AstraZeneca, Vifor Pharma
    Contracted Research: Vifor Pharma

    Mikhail N. Kosiborod, MD
    Professor of Medicine
    Saint Luke's Hospital of Kansas City
    Kansas City, MO

    Research Grant: AstraZeneca, Boehringer Ingelheim
    Consulting Fees: Amarin, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Glytec, Janssen, Merck (Diabetes), Novartis, Novo Nordisk, Sanofi, Vifor Pharma
    Other Research Support: AstraZeneca
    Honorarium: AstraZeneca, Boehringer Ingelheim, Novo Nordisk 

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Ben Caref, PhD, has nothing to disclose.
    • Megan Clem has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Stephanie Wenick has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Explore optimal treatment strategies for managing hyperkalemia in patients with heart failure.
    • Examine the mechanisms of action of novel potassium binders and their potential role in the management of hyperkalemia.
  • Target Audience

    This activity is designed to meet the educational needs of heart failure specialists, cardiologists, primary care physicians, nephrologists, and all other allied healthcare professionals involved in the diagnosis, treatment, and care of heart failure.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by an independent educational grant from Vifor Pharma.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free